LCFA presents lung cancer research grant opportunities to researchers worldwide who present the “best in science” projects in the field. These annual lung cancer research grant awards are 6-figure grants, allowing the researcher to set up a lab, hire personnel and begin to amass data to prove their hypotheses.
LCFA awards research grants to young investigators who present projects that will have the best impact on the lives of lung cancer patients.
2023 LCFA/BMS/IASLC Disparities in Clinical Oncology Research Grants
Funding Opportunity Description
Lung Cancer Foundation of America (“LCFA”) and the International Association for the Study of Lung Cancer (“IASLC”), with financial support from Bristol-Myers Squibb (“BMS”), seek applications for the LCFA/BMS/IASLC Disparities in Clinical Oncology Research Grants.
LCFA, BMS, and IASLC are committed to advancing innovative lung cancer research with a focus on immunotherapy leading to transformative treatment protocols. However, we recognize that not all Young Investigators are represented by the traditional comprehensive cancer research centers which typically make up the NCI pipeline of funding. With these Disparities in Clinical Oncology Research Grants, we aim to fund Young Investigators whose work can directly benefit under-represented populations served by their institutions.
The objective of the LCFA/BMS/IASLC Disparities in Clinical Oncology Research Grants (“Disparities Grants”) is to support research, undertaken by early-career investigators, that aims to improve the care and treatment of under-represented individuals with lung cancers and other thoracic malignancies.
Examples, though not exclusive, include studies that focus on:
- predictive features guiding the selection of patients for different immuno-oncology therapies
- the application of immuno-oncology therapies in combination with standard therapies, such as curative-intent strategies in early-stage disease
- other ways to improve the effectiveness of immuno-oncology therapies or even cure patients with metastatic lung cancer
- facilitating care by minimizing treatment side effects
Education and Experience
At the time of application, eligible applicants must meet these criteria:
- Be a member of the IASLC. Go to https://www.iaslc.org/membership to join or get more information about IASLC Membership.
- If selected, the applicant must maintain their IASLC membership throughout the duration of the grant.
- Serve as faculty of an institution where more than 50% of the patients being served identify as members of under-represented groups.
- Hold a doctoral degree (including PhD, MD, DO, PharmD, ScD or equivalent).
- Academic rank should be at the Instructor, Assistant Professor, or Associate Professor or equivalent level. Full professors (or equivalent) are not eligible.
- May not hold an independent grant of the R21, R01, DOD or comparable type, including project leader on a SPORE or P01.
- For physicians: be within seven years of completion of residency or fellowship.
- For laboratory scientists: be within seven years of completion of post-doctoral work.
NOTE: Exceptions to the seven-year criterion (but not academic rank) can be made for those who may have had interruptions in their career. To request an exemption, contact the IASLC (firstname.lastname@example.org) prior to submission of the application.
The applicant may not currently be or previously have been:
- Recipient of an LCFA grant.
- A Principal Investigator (PI) of a National Institutes of Health (NIH) peer reviewed research grant of at least $125,000 in direct costs per year for a minimum of 3 years. (With the exception of mentored career development grants or grants where the PI is required to be mentored by another investigator).
- A Principal Investigator or Co-Investigator on a NIH competing multi-component research or center grant or cooperative agreement within a P or U series grant (e.g., P01 Program Project Grant, U01 or U19 Research Program
- A Principal Investigator of a peer-reviewed research grant of at least $125,000 in direct costs per year for a minimum of 3 years from any of the organizations listed in the Organizations with Peer Review Funding Systems at: https://cancercenters.cancer.gov/PoliciesResources/PoliciesResources
The foregoing notwithstanding, the following candidates may be eligible:
- Individuals who are currently supported by NIH Mentored Career Development (K) Grants.
- Recipients of ASCO Career Development Grants or mentored career development grants/grants from other organizations.
Note: Applicants must be a member of the IASLC. Go to https://www.iaslc.org/membership to join or get more information about IASLC Membership.
Hear from Dr Triparna Sen talk about how LCFA’s Young Investigator Grant has helped her.
Dr. Triparna Sen, Associate Professor at Icahn School of Medicine at Mount Sinai, New York City, was the recipient of a 2020 LCFA/IASLC/BMS Young Investigator lung cancer research grant. Her research is looking at the immune system to target and eliminate small cell lung cancer, the most aggressive and metastatic form of lung cancer.
Past Lung Cancer Research Grant Awardees
To attract the best and the brightest to the field of lung cancer, LCFA is committed to supporting young investigators with significant grant funding to pursue a long-term project over the course of multiple years. Meet some of our past Award Recipients.